XML 45 R34.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Reporting (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Profitability that are Most Relied Upon by the CODM are Gross Revenue and Net Income (Loss) | The measures of segment profitability that are most relied upon by the CODM are gross revenue and net income (loss), as presented within the table below and reconciled to the unaudited condensed consolidated statements of operations. Additionally, the CODM views the expenses listed below to be significant in their analysis.
|  | Three Months Ended September 30, 2025
|  | Dominari Financial |  |  | Legacy AIkido Pharma |  |  | Consolidated |
Revenue |  | $ | 50,150 |  |  | $ | 671 |  |  | $ | 50,821 |
Operating Costs |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 41,025 |  |  |  | 9,260 |  |  |  | 50,285 |
Professional and consulting fees |  |  | 255 |  |  |  | 1,185 |  |  |  | 1,440 |
Data processing |  |  | 187 |  |  |  | - |  |  |  | 187 |
Other expenses |  |  | (58 | ) |  |  | 566 |  |  |  | 508 |
Income (loss) from operations |  |  | 8,741 |  |  |  | (10,340 | ) |  |  | (1,599 | )
Other (expenses) income |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 497 |  |  |  | 53 |  |  |  | 550 |
Gain on marketable securities |  |  | 1,213 |  |  |  | 157,917 |  |  |  | 159,130 |
Unrealized loss on note receivable |  |  | - |  |  |  | - |  |  |  | - |
Change in fair value of investments |  |  | - |  |  |  | (32,000 | ) |  |  | (32,000 | )
Total other (expenses) income |  |  | 1,710 |  |  |  | 125,970 |  |  |  | 127,680 |
Net income |  | $ | 10,451 |  |  | $ | 115,630 |  |  | $ | 126,081 |
Less: Net income attributable to non-controlling interests |  |  | 871 |  |  |  | - |  |  |  | 871 |
Net income attributable to common stockholders of Dominari Holdings |  | $ | 9,580 |  |  | $ | 115,630 |  |  | $ | 125,210 |
Total assets |  | $ | 83,124 |  |  | $ | 140,322 |  |  | $ | 223,446 |
|  | Three Months Ended September 30, 2024
|  | Dominari Financial |  |  | Legacy AIkido Pharma |  |  | Consolidated |
Revenue |  | $ | 3,684 |  |  | $ | 359 |  |  | $ | 4,043 |
Operating Costs |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 3,798 |  |  |  | 1,613 |  |  |  | 5,411 |
Professional and consulting fees |  |  | 232 |  |  |  | 267 |  |  |  | 499 |
Data processing |  |  | 241 |  |  |  | 32 |  |  |  | 273 |
Other expenses |  |  | 167 |  |  |  | 889 |  |  |  | 1,056 |
Loss from operations |  |  | (754 | ) |  |  | (2,442 | ) |  |  | (3,196 | )
Other (expenses) income |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 204 |  |  |  | 76 |  |  |  | 280 |
Gain on marketable securities |  |  | - |  |  |  | 89 |  |  |  | 89 |
Unrealized loss on note receivable |  |  | - |  |  |  | (429 | ) |  |  | (429 | )
Change in fair value of investments |  |  | - |  |  |  | (955 | ) |  |  | (955 | )
Total other (expenses) income |  |  | 204 |  |  |  | (1,219 | ) |  |  | (1,015 | )
Net loss |  | $ | (550 | ) |  | $ | (3,661 | ) |  | $ | (4,211 | )
Total assets |  | $ | 16,062 |  |  | $ | 27,369 |  |  | $ | 43,431 |
|  | Nine Months Ended September 30, 2025 |
|  | Dominari Financial |  |  | Legacy AIkido Pharma |  |  | Consolidated |
Revenue |  | $ | 92,355 |  |  | $ | 671 |  |  | $ | 93,026 |
Operating Costs |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 78,455 |  |  |  | 59,996 |  |  |  | 138,451 |
Professional and consulting fees |  |  | 1,613 |  |  |  | 2,453 |  |  |  | 4,066 |
Data processing |  |  | 546 |  |  |  | - |  |  |  | 546 |
Other expenses |  |  | 675 |  |  |  | 2,323 |  |  |  | 2,998 |
Income (loss) from operations |  |  | 11,066 |  |  |  | (64,101 | ) |  |  | (53,035 | )
Other (expenses) income |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 878 |  |  |  | 95 |  |  |  | 973 |
Gain on marketable securities |  |  | 4,539 |  |  |  | 158,555 |  |  |  | 163,094 |
Unrealized gain on note receivable |  |  | - |  |  |  | 221 |  |  |  | 221 |
Change in fair value of investments |  |  | - |  |  |  | - |  |  |  | - |
Total other income |  |  | 5,417 |  |  |  | 158,871 |  |  |  | 164,288 |
Net income (loss) |  | $ | 16,483 |  |  | $ | 94,770 |  |  | $ | 111,253 |
Less: Net income attributable to noncontrolling interests |  |  | 1,921 |  |  |  | - |  |  |  | 1,921 |
Net income attributable to common stockholders of Dominari Holdings |  | $ | 14,562 |  |  | $ | 94,770 |  |  | $ | 109,332 |
Total assets |  | $ | 83,124 |  |  | $ | 140,322 |  |  | $ | 223,446 |
|  | Nine Months Ended September 30, 2024 |
|  | Dominari Financial |  |  | Legacy AIkido Pharma |  |  | Consolidated |
Revenue |  | $ | 10,553 |  |  | $ | 1,031 |  |  | $ | 11,584 |
Operating Costs |  |  |  |  |  |  |  |  |  |  |  |
Compensation and benefits |  |  | 10,037 |  |  |  | 4,210 |  |  |  | 14,247 |
Professional and consulting fees |  |  | 993 |  |  |  | 924 |  |  |  | 1,917 |
Data processing |  |  | 616 |  |  |  | 77 |  |  |  | 693 |
Other expenses |  |  | 1,697 |  |  |  | 1,767 |  |  |  | 3,464 |
Loss from operations |  |  | (2,790 | ) |  |  | (5,947 | ) |  |  | (8,737 | )
Other (expenses) income |  |  |  |  |  |  |  |  |  |  |  |
Interest income |  |  | 545 |  |  |  | 184 |  |  |  | 729 |
Gain on marketable securities |  |  | - |  |  |  | 767 |  |  |  | 767 |
Unrealized loss on note receivable |  |  | - |  |  |  | (2,086 | ) |  |  | (2,086 | )
Change in fair value of investments |  |  | - |  |  |  | (6,445 | ) |  |  | (6,445 | )
Total other (expenses) income |  |  | 545 |  |  |  | (7,580 | ) |  |  | (7,035 | )
Net loss |  | $ | (2,245 | ) |  | $ | (13,527 | ) |  | $ | (15,772 | )
Total assets |  | $ | 16,062 |  |  | $ | 27,369 |  |  | $ | 43,431 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration